Novartis

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world.

www.novartis.com

Novartis RSS Channel

List of articles in category Novartis
Title	Published Date
Novartis delivers excellent performance in third quarter	22 October 2010
Novartis affirms commitment to sustain efforts toward final elimination of leprosy	13 October 2010
Novartis announces agreement to develop influenza vaccines	08 October 2010
Novartis obtains CHMP positive opinion for its investigational pre-pandemic influenza vaccine Aflunov®	28 September 2010
Novartis announces Russian regulatory approval for Gilenya®	13 September 2010
Novartis delivers strong financial performance in second quarter	20 July 2010
Novartis gains new indication for Diovan®* for the treatment of children and adolescents	03 May 2010
Novartis receives approval in the European Union for Menveo®	22 March 2010
Novartis oral MS therapy FTY720 shows reduced risk of confirmed disability progression	25 January 2010
Novartis set to sustain its leading global position in oncology	10 December 2009
Novartis receives approval in the European Union for Onbrez® Breezhaler®	08 December 2009
Novartis receives regulatory approval in Germany for Celtura®	11 November 2009
Novartis announces USD 1 billion investment to build largest pharmaceutical R&D institute in China	04 November 2009
Novartis unveils Lab of Future concept to top European students at Biotechnology Leadership Camp (BioCamp)	27 August 2009
Afinitor® approved in EU as first treatment proven to benefit patients with advanced kidney cancer	10 August 2009
Novartis delivers strong operational performance in the first half of 2009	20 July 2009
Once-yearly Aclasta® approved in EU to treat osteoporosis	29 June 2009
Sandoz to acquire EBEWE Pharma specialty generics business	25 May 2009
Glivec® approved in EU as first post-surgery therapy	08 May 2009
Novartis expects strong operational performance in 2009	27 April 2009

Page 6 of 7